227 related articles for article (PubMed ID: 32725245)
21. Delivery routes matter: Safety and efficacy of intratumoral immunotherapy.
De Lombaerde E; De Wever O; De Geest BG
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188526. PubMed ID: 33617921
[TBL] [Abstract][Full Text] [Related]
22. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
Chesney J; Awasthi S; Curti B; Hutchins L; Linette G; Triozzi P; Tan MCB; Brown RE; Nemunaitis J; Whitman E; Windham C; Lutzky J; Downey GF; Batty N; Amatruda T
Melanoma Res; 2018 Feb; 28(1):44-51. PubMed ID: 29176501
[TBL] [Abstract][Full Text] [Related]
23. Image-guided intratumoral immunotherapy: Developing a clinically practical technology.
Som A; Rosenboom JG; Chandler A; Sheth RA; Wehrenberg-Klee E
Adv Drug Deliv Rev; 2022 Oct; 189():114505. PubMed ID: 36007674
[TBL] [Abstract][Full Text] [Related]
24. Surgical Resection After Talimogene Laherparepvec for Melanoma: Persistent Fuorodeoxyglucose Avidity on Positron Emission Tomography Despite No Viable Disease.
MacArthur TA; Fahy AS; Jakub JW
Am Surg; 2021 Jun; 87(6):849-854. PubMed ID: 34060947
[TBL] [Abstract][Full Text] [Related]
25. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
26. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
27. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety.
Raman SS; Hecht JR; Chan E
Immunotherapy; 2019 Jun; 11(8):705-723. PubMed ID: 31045464
[TBL] [Abstract][Full Text] [Related]
28. Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma.
Hoffner B; Iodice GM; Gasal E
Oncol Nurs Forum; 2016 Mar; 43(2):219-26. PubMed ID: 26906132
[TBL] [Abstract][Full Text] [Related]
29. Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer.
Tsai EB; Pomykala K; Ruchalski K; Genshaft S; Abtin F; Gutierrez A; Kim HJ; Li A; Adame C; Jalalian A; Wolf B; Garon EB; Goldman JW; Suh R
Radiology; 2018 Apr; 287(1):326-332. PubMed ID: 29232184
[TBL] [Abstract][Full Text] [Related]
30. Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer.
Chua CYX; Jain P; Susnjar A; Rhudy J; Folci M; Ballerini A; Gilbert A; Singh S; Bruno G; Filgueira CS; Yee C; Butler EB; Grattoni A
J Control Release; 2018 Sep; 285():23-34. PubMed ID: 30008369
[TBL] [Abstract][Full Text] [Related]
31. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience.
Perez MC; Miura JT; Naqvi SMH; Kim Y; Holstein A; Lee D; Sarnaik AA; Zager JS
Ann Surg Oncol; 2018 Dec; 25(13):3960-3965. PubMed ID: 30298318
[TBL] [Abstract][Full Text] [Related]
32. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
[TBL] [Abstract][Full Text] [Related]
33. Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography.
Mortensen MB
Dan Med J; 2012 Dec; 59(12):B4568. PubMed ID: 23290296
[TBL] [Abstract][Full Text] [Related]
34. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.
Louie RJ; Perez MC; Jajja MR; Sun J; Collichio F; Delman KA; Lowe M; Sarnaik AA; Zager JS; Ollila DW
J Am Coll Surg; 2019 Apr; 228(4):644-649. PubMed ID: 30690076
[TBL] [Abstract][Full Text] [Related]
35. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL
J Clin Oncol; 2018 Jun; 36(17):1658-1667. PubMed ID: 28981385
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels.
Rochlitz C; Dreno B; Jantscheff P; Cavalli F; Squiban P; Acres B; Baudin M; Escudier B; Heinzerling L; Morant R; Herrmann R; Dietrich PY; Dummer R
Cancer Gene Ther; 2002 Mar; 9(3):289-95. PubMed ID: 11896446
[TBL] [Abstract][Full Text] [Related]
37. Intratumoral Immunotherapy for Early-stage Solid Tumors.
Hong WX; Haebe S; Lee AS; Westphalen CB; Norton JA; Jiang W; Levy R
Clin Cancer Res; 2020 Jul; 26(13):3091-3099. PubMed ID: 32071116
[TBL] [Abstract][Full Text] [Related]
38. Extensive Pigment Incontinence Mimicking Persistent Melanoma After Talimogene Laherparepvec Therapy.
Danesh M; Faulkner-Jones B; Desai A; Kim CC
JAMA Dermatol; 2019 Apr; 155(4):496-497. PubMed ID: 30758504
[No Abstract] [Full Text] [Related]
39. Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients.
Tselikas L; Dardenne A; de Baere T; Faron M; Ammari S; Farhane S; Suzzoni S; Danlos FX; Raoult T; Susini S; Al Shatti N; Mouraud S; Deschamps F; Kobe A; Delpla A; Roux C; Baldini C; Soria JC; Barlesi F; Massard C; Robert C; Champiat S; Marabelle A
Eur J Cancer; 2022 Sep; 172():1-12. PubMed ID: 35724442
[TBL] [Abstract][Full Text] [Related]
40. Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma.
Albertini MR; Ranheim EA; Zuleger CL; Sondel PM; Hank JA; Bridges A; Newton MA; McFarland T; Collins J; Clements E; Henry MB; Neuman HB; Weber S; Whalen G; Galili U
Cancer Immunol Immunother; 2016 Aug; 65(8):897-907. PubMed ID: 27207605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
